| 23.99 0 (0%) | 12-05 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 28.02  |
1-year : | 32.72 |
| Resists | First : | 23.98 |
Second : | 28.02 |
| Pivot price | 23.79 |
|||
| Supports | First : | 23.24 |
Second : | 22.79 |
| MAs | MA(5) : | 23.97 |
MA(20) : | 23.62 |
| MA(100) : | 22.98 |
MA(250) : | 19.1 |
|
| MACD | MACD : | 0.2  |
Signal : | 0.2 |
| %K %D | K(14,3) : | 99.4 |
D(3) : | 99.2 |
| RSI | RSI(14): 73.1 |
|||
| 52-week | High : | 25.31 | Low : | 12.47 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ ABCM ] has closed below upper band by 34.4%. Bollinger Bands are 18.6% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 24.02 - 24.11 | 24.11 - 24.2 |
| Low: | 23.74 - 23.85 | 23.85 - 23.97 |
| Close: | 23.81 - 23.98 | 23.98 - 24.15 |
Abcam plc, a life science company, focuses on identifying, developing, and distributing reagents and tools for scientific research, diagnostics, and drug discovery. Its principal products include primary and secondary antibodies; conjugated antibodies and conjugation kits; singleplex and multiplex immunoassays; proteins and peptides that include cytokines; edited cell lines and lysates; and various other products, including cellular activity kits, miRNA kits, biochemicals, and cell signaling pathway tools. The company serves scientists and researchers in academic institutions and research institutes, as well as in pharmaceutical, biotechnology, and diagnostics companies. It has operations in the Americas, Europe, the Middle East, Africa, China, Japan, and rest of the Asia Pacific. The company sells its products online. Abcam plc was incorporated in 1998 and is headquartered in Cambridge, the United Kingdom.
Mon, 04 Dec 2023
Durable Capital Partners LP Has $351.69 Million Stock Position in Abcam plc (NASDAQ:ABCM) - MarketBeat
Mon, 04 Dec 2023
Acquisition of Abcam by Danaher Approved by the High Court of Justice of England and Wales – Abcam plc - Abcam plc
Fri, 01 Dec 2023
Is Abcam PLC (ABCM) Stock About to Get Hot Friday? - InvestorsObserver
Mon, 27 Nov 2023
Does Abcam PLC (ABCM) Have What it Takes to be in Your Portfolio Monday? - InvestorsObserver
Wed, 15 Nov 2023
Here's Headwaters Capital's Perspective on Abcam plc (ABCM) Acquisition - Yahoo Finance
Wed, 08 Nov 2023
Here's Why Baron Discovery Fund Sold Abcam plc (ABCM) - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 230 (M) |
| Shares Float | 192 (M) |
| Held by Insiders | 6.4 (%) |
| Held by Institutions | 88.2 (%) |
| Shares Short | 4,080 (K) |
| Shares Short P.Month | 2,900 (K) |
| EPS | 0 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 3.14 |
| Profit Margin | 0.6 % |
| Operating Margin | 18.3 % |
| Return on Assets (ttm) | 4.3 % |
| Return on Equity (ttm) | 0.3 % |
| Qtrly Rev. Growth | 9.6 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 1.64 |
| EBITDA (p.s.) | 0.46 |
| Qtrly Earnings Growth | 188 % |
| Operating Cash Flow | 26 (M) |
| Levered Free Cash Flow | 29 (M) |
| PE Ratio | 2399 |
| PEG Ratio | 0 |
| Price to Book value | 7.64 |
| Price to Sales | 14.54 |
| Price to Cash Flow | 210.73 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|